VIAL
Compound comparison

Ipamorelin vs Tesamorelin

Ipamorelin and Tesamorelin are both peptide compounds evaluated on Vial: Ipamorelin is available as a compounded preparation with clinical-trial evidence, and Tesamorelin is available as a compounded preparation with clinical-trial evidence, offered by 20 and 3 verified providers respectively.

Vial summary · compiled from public records

At a glance

Ipamorelin

Category
Peptide
FDA / legal status
Compoundable
Route
Subcutaneous
20providers on Vial →

Tesamorelin

Sold as Egrifta

Category
Peptide
FDA / legal status
Compoundable
Route
Subcutaneous
3providers on Vial →

Side by side

FieldIpamorelinTesamorelin
CategoryPeptidePeptide
Brand namesEgrifta
FDA / legal statusCompoundableCompoundable
Evidence tierClinical TrialsClinical Trials
Administration routeSubcutaneousSubcutaneous
Compounding accessAvailable through 503A and 503B compounding pharmaciesAvailable through 503A and 503B compounding pharmacies
Providers on Vial20 listed3 listed
Typical price band$$ to $$$$$ to $$$

Verified providers offering each

Ranked by Confidence Rating, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.

85+ High Confidence70 to 84 Well Documented50 to 69 Limited ConfidenceUnder 50 Flagged

About each compound

About Ipamorelin

A synthetic pentapeptide growth hormone secretagogue, ipamorelin selectively stimulates pituitary release of growth hormone by mimicking ghrelin and binding to the growth hormone secretagogue receptor (GHS-R). Unlike earlier secretagogues, it demonstrates high selectivity for GH release with minimal effect on cortisol, prolactin, or appetite-regulating hormones. Research applications have focused on its potential use in growth hormone deficiency, age-related muscle loss, and bone metabolism studies.

About Tesamorelin

Tesamorelin is an FDA-approved GHRH analog indicated for HIV-associated lipodystrophy and is used off-label in optimization medicine for visceral fat reduction and cognitive enhancement. Clinical data shows significant reductions in visceral adipose tissue and emerging evidence suggests neuroprotective benefits in older adults. It produces stronger and more sustained GH elevation than sermorelin. Compounded versions are available through licensed pharmacies.

Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.

This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.

Related compound comparisons

Other comparisons in the same category.

All compound comparisons →